共 50 条
- [1] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study[J]. CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648Mao, LiliFang, MeiyuChen, YuWei, XiaotingCao, JunLin, JingZhang, PengChen, LingCao, XiaoChen, YujunGuo, JunSi, Lu
- [2] Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Mao, LiliDai, JieBai, XueKong, YanSheng, XinanChi, ZhihongCui, ChuanliangLian, BinTang, BixiaYan, XieqiaoWang, XuanLi, SimingZhou, LiWei, XiaotingLi, JuanLi, CailiDuan, RongXu, HuayanGuo, JunSi, Lu
- [3] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer[J]. CANCER, 2021, 127 (21) : 3975 - 3984Xu, JianmingBai, YuxianSun, HuichuanBai, ChunmeiJia, RuLi, YiZhang, WenjieLiu, LeiHuang, ChengGuan, MeiZhou, JinghongSu, Weiguo
- [4] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Bai, YuxianXu, JianmingSun, HuichuanBai, ChunmeiJia, RuLi, YiZhang, WenjieLiu, LeiHuang, ChengGuan, MeiZhou, JinghongSu, Weiguo
- [5] Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study[J]. ANNALS OF ONCOLOGY, 2017, 28 (03) : 634 - 641McArthur, G. A.Maio, M.Arance, A.Nathan, P.Blank, C.Avril, M. -F.Garbe, C.Hauschild, A.Schadendorf, D.Hamid, O.Fluck, M.Thebeau, M.Schachter, J.Kefford, R.Chamberlain, M.Makrutzki, M.Robson, S.Gonzalez, R.Margolin, K.
- [6] Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Si, LuZou, ZhengyunZhang, WeizhenFang, MeiyuZhang, XiaoshiLuo, ZhiguoChen, JingHuang, GangZhang, PengCheng, YingLiu, JiweiLiu, JiyanZhang, JunpingWu, DiChen, YuMa, XiaobiaoWei, XiaotingSun, PengJia, ZhongweiGuo, Jun
- [7] Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Si, LuFang, MeiyuChen, YuMao, LiliZhang, PengLin, JingBai, XueCao, XiaoChen, YiGuo, Jun
- [8] Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study [J]. LANCET ONCOLOGY, 2023, 24 (04): : E145 - E145
- [9] Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study[J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5340 - 5351Zager, Jonathan S.Orloff, MarlanaFerrucci, Pier FrancescoChoi, JunsungEschelman, David J.Glazer, Evan S.Ejaz, AslamHoward, J. HarrisonRichtig, ErikaOchsenreither, SebastianReddy, Sunil A.Lowe, Michael C.Beasley, Georgia M.Gesierich, AnjaBender, ArminGschnell, MartinDummer, ReinhardRivoire, MichelArance, AnaFenwick, Stephen WilliamSacco, Joseph J.Haferkamp, SebastianWeishaupt, CarstenJohn, JohnnyWheater, MatthewOttensmeier, Christian H.
- [10] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13Zimmer, LisaEigentler, Thomas K.Kiecker, FelixSimon, JanUtikal, JochenMohr, PeterBerking, CarolaKaempgen, EckhartDippel, EdgarStadler, RudolfHauschild, AxelFluck, MichaelTerheyden, PatrickRompel, RainerLoquai, CarmenAssi, ZeinabGarbe, ClausSchadendorf, Dirk